氢氯吡格雷联合尼膜同治疗短暂性脑缺血发作的临床效果分析

发布时间：2018-10-13 14:01

【摘要】：目的探讨氢氯吡格雷联合尼膜同治疗短暂性脑缺血发作(TIA)的有效性和安全性。方法 2012年1月1日至2016年8月1日该科及神经内科门诊和住院TIA患者159例,分为3组。A组43例,口服氢氯吡格雷联合阿司匹林治疗;B组51例,口服氢氯吡格雷联合尼莫地平片治疗;C组65例,口服氢氯吡格雷联合尼膜同治疗。观察3组患者疗效,比较3组治疗前后凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、纤维蛋白原(FIB)、血小板数目(PLT)的差异,以及出血性事件的发生率。结果 A、C组治疗的总有效率明显优于B组(P0.05),A组和C组治疗效果差异无统计学意义(P0.05)。B组和C组对凝血的影响优于A组(P0.05)。3组患者均未出现严重出血事件(脑出血等),差异无统计学意义(P0.05)。结论氢氯吡格雷联合尼膜同片能明显降低TIA的频率,对患者凝血指标影响较小,安全有效。
[Abstract]:Objective to investigate the efficacy and safety of hydroclopidogrel combined with nitriline membrane in the treatment of transient ischemic attack (TIA). Methods from January 1, 2012 to August 1, 2016, 159 TIA patients were divided into three groups: group A (43 cases) treated with oral hydroclopidogrel combined with aspirin, group B (51 cases), group B (51 cases). The patients in group C were treated with hydroclopidogrel combined with nimodipine, and group C with hydroclopidogrel combined with nimodipine. To observe the curative effect of three groups, compare the difference of thrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (FIB), platelet number (PLT), and the incidence of hemorrhagic events before and after treatment. Results the total effective rate of treatment in group C was significantly better than that in group B (P0.05), A group and group C had no significant difference in the effect of treatment (P0.05) and group C had better effect on coagulation than group A (P0.05). There were no severe hemorrhage events (cerebral hemorrhage, etc.) in group 3. The difference was not statistically significant (P0.05). Conclusion Hydroclopidogrel combined with nitriline membrane tablets can significantly reduce the frequency of TIA, and has little effect on the coagulation index, and is safe and effective.
【作者单位】：川北医学院第二临床学院/四川省南充市中心医院神经外科;
【分类号】：R743.31

【相似文献】